Drug Profile
LB 301
Alternative Names: LB-301; mLB-301Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator LogicBio Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; UGT1A1 enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Crigler-Najjar syndrome
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Crigler-Najjar-syndrome in USA (Parenteral)
- 16 Nov 2022 LogicBio Therapeutics has been acquired by Alexion AstraZeneca Rare Disease
- 10 Jan 2020 LogicBio Therapeutics enters into a research collaboration with Takeda to develop LB 301 for Crigler-Najjar Syndrome